SCHEMBL14955704

SCHEMBL14955704

Cc1ccc2c(N)c(C(=O)Nc3ccccc3C(F)(F)F)sc2n1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.60
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
TP53 P04637 1/20 0.54
POLB P06746 1/20 0.54
IKBKB O14920 1/20 0.54
LIMK1 P53667 1/20 0.54
ALDH1A1 P00352 4/20 0.53
NPSR1 Q6W5P4 2/20 0.53
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
USP28 Q96RU2 6/20 0.51
LMNA P02545 1/20 0.51
USP25 Q9UHP3 4/20 0.50
KDM4E B2RXH2 3/20 0.50
RECQL P46063 1/20 0.50
TLR9 Q9NR96 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
HPGD P15428 1/20 0.50
MCL1 Q07820 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10016378 0.83 NPC1 (0.76) MAPTNPC1RAB9APOLBALDH1A1
SCHEMBL13186308 0.83 MAPT (0.62) MAPTNPC1RAB9ATP53POLB
SCHEMBL14955295 0.83 MAPT (0.74) MAPTNPC1RAB9ATP53POLB
SCHEMBL14955161 0.82 ADORA2A (0.58) MAPTNPC1RAB9ATP53POLB
SCHEMBL14954689 0.82 MAPT (0.74) MAPTNPC1RAB9ATP53POLB
SCHEMBL16071463 0.80 MAPT (0.67) MAPTNPC1RAB9ATP53POLB
SCHEMBL14954720 0.80 MAPT (0.77) MAPTNPC1RAB9ATP53POLB
SCHEMBL14955291 0.79 TDP1 (0.65) MAPTNPC1RAB9ATP53POLB
SCHEMBL30598365 0.79 TDP1 (0.65) MAPTNPC1RAB9ATP53POLB
SCHEMBL30598364 0.79 TDP1 (0.65) MAPTNPC1RAB9ATP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2017-05-04 US disclosed
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2017-05-04 US disclosed
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2017-05-04 US disclosed
WO-2014089378-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2014-06-12 WO disclosed
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. (US) 2013-05-23 US disclosed
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. (US) 2013-05-23 US disclosed
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. (US) 2013-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections TTPA, TPMT, SLC19A2 MAPT 85/4885NPC1 1976/4885RAB9A 1518/4885
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS TTPA, TPMT, SLC19A2 MAPT 85/4885NPC1 1976/4885RAB9A 1518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.